Novogen renegotiates timing of Marshall Edwards' license payment for phenoxodiol

New York, June 7 - Novogen Ltd. said it has renegotiated the timing of an $8 million milestone license payment for phenoxodiol payable to Novogen in December by Marshall Edwards, Inc.

The amendment postpones the payment until phenoxodiol receives first approval for marketing the product in the United States or any other country.

The marketing approval may be by the receipt of a New Drug Application under accelerated approval or otherwise.

Marshall Edwards said the postponement is to enable Marshall Edwards to focus its cash resources on completing the phase 3 clinical trial for which it recently received approval of its Special Protocol Assessment from the Food and Drug Administration.

Marshall Edwards is a Stamford, Conn., clinical oncology company majority owned by Novogen. Novogen is based in Sydney, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.